Clinical Pharmacology & Therapeutics · 1974 · 30 citations · 0 references
PharmacyPharmacokineticsPharmacologyBioavailabilityClinical PharmacologyDrug ClearanceDrug DispositionMultiple-dose PharmacokineticsDrug Disposition PharmacokineticsRebound BehaviorRebound DynamicsUrinary EliminationUrinary Excretion KineticsUrinary Output
In the first part of this study patients received constant daily doses of diphenylhydantoin (DPH) during oral, intramuscular, and subsequent oral periods. The data demonstrate that there is a profound fall in plasma DPH levels and urinary 5‐(p‐hydroxyphenyl)‐5‐ phenylhydantoin (HPPH) excretion after intramuscular (IM) administration and that this fall is followed by significant rebound when oral administration is resumed. The second part presents data for a regimen, confirmed by clinical and laboratory findings, for switching from oral to IM dosage and back without dramatic changes in plasma DPH levels or urinary HPPH excretion.